Materialise (MTLS) Q2 2026 Earnings Call Transcript

Materialise reported Q2 revenue of EUR 70.1m (+8% YoY) with adjusted EBIT of EUR 3.9m, expanding margin to 5.5% from operating leverage. For H1, net profit swung to EUR 5.2m (from a EUR 0.34m net loss), while full-year guidance was increased: adjusted EBIT to EUR 12m–14m (vs EUR 10m–12m prior), and revenue guidance reaffirmed at EUR 273m–283m for 2026 despite RapidFit and Eyewear divestments. Software revenue declined to EUR 19.2m (-2.1% H1) amid cautious industrial spending and reduced U.S. research grants, but recurring software reached 86% of Q2 software revenue as CO-AM Pro was launched on May 15 (1 month early). The company ended Q2 with EUR 133.7m cash and a net cash position of EUR 74.2m after EUR 5.2m spent on buybacks (about 1.1m ADS), supporting a positive profitability and balance-sheet read-through for investors.

Analysis

The market should view this less as a one-quarter beat and more as evidence that the business is migrating toward higher-quality, more defensible revenue. The real winners are the parts of the additive-manufacturing stack tied to regulated, repeatable workflows: MTLS’s software layer, certified aerospace production, and hospital-integrated medical tooling. That shift is a headwind for commoditized prototyping shops and smaller niche service bureaus that depend on discretionary capex cycles; their pricing power gets worse as customers consolidate around vendors that can prove compliance, automation, and throughput.

Near term, the stock’s reaction is likely driven by the guide raise and cash conversion, but the next catalyst is whether CO-AM turns into a measurable attach-rate story rather than a roadmap story. The key risk is that management is already telling us software demand remains soft where budgets depend on grants and reimbursement; if those end markets do not normalize over the next 1-3 quarters, the “subscription transition” may just offset decline rather than create acceleration. Over 6-18 months, sustained margin expansion depends on keeping R&D disciplined; if working capital builds or the hardware mix shifts back toward lower-margin prototype work, the cash narrative will fade quickly.

Consensus may be missing that the most valuable change is portfolio quality, not top-line growth. The stock looks under-owned if investors still frame MTLS as a cyclical 3D-printing proxy; it looks overdone only if they extrapolate a full medical software reacceleration without a recovery in U.S. academic funding and orthopedics reimbursement. Falsifiers: a 2H revenue slowdown, EBIT guidance cut back toward the prior range, or evidence that CO-AM adoption is not translating into higher recurring revenue by the next two quarters.

Key Decisions for Investors

• Buy MTLS on a 3-5 session post-earnings fade if the stock holds the gap; use a 6-12 month horizon and size for a mid-teens upside scenario versus low-double-digit downside if guidance reverts.
• For traders, consider MTLS upside call spreads into the next print to express the thesis that recurring software and medical mix improve, while capping premium outlay if the market remains skeptical.
• Set a watch item on MTLS recurring software growth and CO-AM NPI/Enterprise adoption over the next 1-2 quarters; if those fail to inflect, exit the thesis rather than averaging down.
• Do not chase the move if the stock re-rates materially above the implied earnings uplift; the business still has end-market concentration risk in U.S. academic medical software and prototyping.